REMS for Oploids Considered

August 2010
Pharmaceutical Representative;Aug2010, Vol. 40 Issue 8, p11
The article reports that Food and Drug Administration's (FDA's) meeting of the Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees has provided the attendees with a 374-page briefing on a possible Risk Evaluation and Mitigation Strategy (REMS) for prescription opioids in the U.S.


Related Articles

  • FDA looking to add REMS for certain opioids.  // Pharmacy Today;Mar2009, Vol. 15 Issue 3, p1 

    The article reports on the move of the Food and Drug Administration (FDA) to require drug manufacturers a Risk Evaluation and Management Strategy (REMS) for opioid drug products in the U.S. The program is to reduce the frequency of drug misuse, abuse and accidental overdose through the...

  • Mitigating the Safety Risks of Drugs With a Focus on Opioids: Are Risk Evaluation and Mitigation Strategies the Answer? Brooks, Marta J. // Mayo Clinic Proceedings;Dec2014, Vol. 89 Issue 12, p1673 

    Approximately 40% of all newly approved drugs are subject to safety restrictions inclusive of Risk Evaluation and Mitigation Strategies (REMS), which were created with the US Food and Drug Administration Amendments Act of 2007. This law expanded Food and Drug Administration (FDA) authority to...

  • Prescriber training on safe use of long-acting opioids required with new REMS. Foxhall, Kathryn // Drug Topics;May2011, Vol. 155 Issue 5, p24 

    The article reports on the announcement made by the U.S. Food and Drug Administration (FDA) that it would require a Risk Evaluation and Mitigation Strategy (REMS) for all long-acting and extended release opioids. It calls for Congress to mandate within two years that prescribers must complete...

  • Risk-management plan for opioid drugs proves slow going. Traynor, Kate // American Journal of Health-System Pharmacy;7/15/2009, Vol. 66 Issue 14, p1242 

    The article reports on the move of the Food and Drug Administration (FDA) to create a Risk Evaluation and Mitigation Strategy (REMS) for drugs in the U.S. REMS has been intended to assure the safe use of the opioid drugs. Details on the objectives of the said strategy are also considered in the...

  • How to safely prescribe long-acting opioids. Gregory, Thomas B. // Journal of Family Practice;Dec2013, Vol. 62 Issue 12, pS12 

    The article discusses safe prescription of long-acting opioids. It mentions the Drug Abuse Warning Network statistics which shows that 1.3 million of 4.9 million drug-related emergency department (ED) visits in 2010 were for abuse or misuse of pharmaceuticals. It says that the U.S. Food and Drug...

  • Medication Safety: An AAOS Priority. MCCLURE-THOMAS, DANA; ZEMAITIS, PAUL; RING, DAVID C. // AAOS Now;Dec2013, Vol. 7 Issue 12, p42 

    The article focuses on the task of the American Academy of Orthopaedic Surgeons (AAOS) Patient Safety Committee to educate members about the safety issues associated with prescription medication. It states that AAOS educate members through monitoring alerts from the U.S. Food and Drug...

  • FDA goes after illegal Cipro Web sites. Dickinson, James G. // Medical Marketing & Media;Dec2001, Vol. 36 Issue 12, p22 

    Reports on the issuance of warning letters to foreign Web site operators selling illegal generic ciprofloxacin in the U.S. Protection to the public from harmful drugs; Inability of the Food and Drugs Administration to determine the specification of the drugs marketed by the Web sites.

  • Drug Safety Concerns Shape Manufacturing Policy. Wechsler, Jill // Pharmaceutical Technology Europe;Mar2002, Vol. 14 Issue 3, p13 

    Reports on the move of the U.S. Food and Drug Administration to improve processes for evaluating the risk factors in new drug candidates and for tracking and evaluating adverse events once a product is on the market. Effect of the campaign of the agency on the manufacturing process of the...

  • Drug Safety Alerts Almost Double. J. G. D. // Medical Marketing & Media;Jun2012, Vol. 47 Issue 6, p32 

    The article focuses on a report released by the U.S. Food and Drug Administration (FDA) which reflects the increase of drug safety alerts in the country in 2011.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics